PRM — Big Pharma Split Cashflow Statement
0.000.00%
Last trade - 00:00- CA$13.30m
- -CA$12.91m
- CA$0.66m
- 76
- 81
- 40
- 72
Annual cashflow statement for Big Pharma Split, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.217 | 4.21 | 2.39 | -0.645 | -0.539 |
| Non-Cash Items | 0.406 | -5.45 | -5.29 | 0.277 | -0.754 |
| Unusual Items | |||||
| Changes in Working Capital | 4.16 | -7.76 | 4.03 | 12.2 | 3 |
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 4.35 | -9 | 1.13 | 11.9 | 1.71 |
| Financing Cash Flow Items | — | -0.291 | -0.002 | 0 | -0.009 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | -4.65 | 10.2 | -1.74 | -12.5 | -0.882 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.305 | 1.2 | -0.611 | -0.615 | 0.826 |